Overview

Pembrolizumab Alone or in Combination With Ipatasertib for the Treatment of Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Status:
Not yet recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well pembrolizumab alone or in combination with ipatasertib works in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or has spread to other places in the body (metastatic). Ipatasertib is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ipatasertib in combination with pembrolizumab may kill more tumor cells in patients with recurrent/metastatic squamous cell cancer of the head and neck.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Pembrolizumab